Literature DB >> 23224422

Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Jan-Peter van Wieringen1, Jan Booij, Vladimir Shalgunov, Philip Elsinga, Martin C Michel.   

Abstract

Dopamine D(2) receptors, similar to other G-protein-coupled receptors, exist in a high- and low-affinity state for agonists. Based upon a review of the methods for detecting D(2) receptor agonist high-affinity states, we discuss alterations of such states in animal models of disease and the implications of such alterations for their labelling with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) tracers. The classic approach of detecting agonist high-affinity states compares agonist competition for antagonist radioligands, in most cases using [(3)H]-spiperone as the radioligand; alternative approaches and radioligands have been proposed, but their claimed advantages have not been substantiated by other investigators. In view of the advantages and disadvantages of various techniques, we critically have reviewed reported findings on the detection of D(2) receptor agonist high-affinity states in a variety of animal models. These data are compared to the less numerous findings from human in vivo studies based on PET and SPECT tracers; they are interpreted in light of the finding that D(2) receptor agonist high-affinity states under control conditions may differ between rodent and human brain. The potential advantages of agonist ligands in studies of pathophysiology and as diagnostics are being discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23224422     DOI: 10.1007/s00210-012-0817-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  151 in total

1.  Dopamine D2 receptor dimer formation: evidence from ligand binding.

Authors:  D Armstrong; P G Strange
Journal:  J Biol Chem       Date:  2001-02-23       Impact factor: 5.157

Review 2.  Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

Authors:  P G Strange
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

3.  Ketamine/xylazine anesthesia alters [11C]MNPA binding to dopamine D2 receptors and response to methamphetamine challenge in monkey brain.

Authors:  Hiroyuki Ohba; Norihiro Harada; Shingo Nishiyama; Takeharu Kakiuchi; Hideo Tsukada
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

4.  D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.

Authors:  Teng Peng; John Zysk; Peter Dorff; Charles S Elmore; Peter Ström; Jonas Malmquist; Min Ding; David Tuke; Jennifer Werkheiser; Dan Widzowski; Ladislav Mrzljak; Donna Maier
Journal:  Synapse       Date:  2010-08       Impact factor: 2.562

5.  Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).

Authors:  L A van Vliet; N Rodenhuis; D Dijkstra; H Wikström; T A Pugsley; K A Serpa; L T Meltzer; T G Heffner; L D Wise; M E Lajiness; R M Huff; K Svensson; S Sundell; M Lundmark
Journal:  J Med Chem       Date:  2000-07-27       Impact factor: 7.446

6.  Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907.

Authors:  H Hall; C Halldin; D Dijkstra; H Wikström; L D Wise; T A Pugsley; P Sokoloff; S Pauli; L Farde; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

7.  Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein.

Authors:  Paul Cumming; Dean F Wong; Nicholas Gillings; John Hilton; Ursula Scheffel; Albert Gjedde
Journal:  J Cereb Blood Flow Metab       Date:  2002-05       Impact factor: 6.200

Review 8.  Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

Authors:  M Laruelle
Journal:  Q J Nucl Med       Date:  1998-09

9.  Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding.

Authors:  K A Metwally; M Dukat; C T Egan; C Smith; A DuPre; C B Gauthier; K Herrick-Davis; M Teitler; R A Glennon
Journal:  J Med Chem       Date:  1998-12-03       Impact factor: 7.446

10.  Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.

Authors:  Philip Seeman; Teresa Tallerico; Françoise Ko
Journal:  Synapse       Date:  2003-09-15       Impact factor: 2.562

View more
  12 in total

1.  Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Authors:  Isabelle Boileau; Doris Payer; Pablo M Rusjan; Sylvain Houle; Junchao Tong; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

Review 2.  Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?

Authors:  Katerina Okeke; Stephane Angers; Michel Bouvier; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

Review 3.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

4.  Convenient synthesis of 18F-radiolabeled R-(-)-N-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphine.

Authors:  Anna W Sromek; Shaohui Zhang; Vamsidhar Akurathi; Alan B Packard; Wei Li; David Alagille; Thomas J Morley; Ronald Baldwin; Gilles Tamagnan; John L Neumeyer
Journal:  J Labelled Comp Radiopharm       Date:  2014-11-17       Impact factor: 1.921

Review 5.  The role of D2-autoreceptors in regulating dopamine neuron activity and transmission.

Authors:  C P Ford
Journal:  Neuroscience       Date:  2014-01-23       Impact factor: 3.590

6.  Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Carol Borlido; Gary Remington; Philip Gerretsen; Alan Wilson; Sylvain Houle; Mahesh Menon; David Mamo; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2014-05-30       Impact factor: 7.853

7.  Synthesis and evaluation in rats of homologous series of [(18)F]-labeled dopamine D 2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers.

Authors:  Vladimir Shalgunov; Jan-Peter van Wieringen; Henk M Janssen; P Michel Fransen; Rudi A J O Dierckx; Martin C Michel; Jan Booij; Philip H Elsinga
Journal:  EJNMMI Res       Date:  2015-07-25       Impact factor: 3.138

8.  Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors.

Authors:  Jan-Peter van Wieringen; Kora de Bruin; Henk M Janssen; P Michel Fransen; Anton G M Janssen; Peter A van Doremalen; Martin C Michel; Philip H Elsinga; Jan Booij
Journal:  Int J Mol Imaging       Date:  2014-12-25

9.  Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.

Authors:  Jonathan M DuBois; Olivier G Rousset; Marie-Christine Guiot; Jeffery A Hall; Andrew J Reader; Jean-Paul Soucy; Pedro Rosa-Neto; Eliane Kobayashi
Journal:  Cereb Cortex       Date:  2016-10-17       Impact factor: 5.357

Review 10.  Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.

Authors:  Vladimir Shalgunov; Aren van Waarde; Jan Booij; Martin C Michel; Rudi A J O Dierckx; Philip H Elsinga
Journal:  Med Res Rev       Date:  2018-11-18       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.